EUVIMEDEUVIMED entdecken
Crossref

Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients

Elisio Costa, Susana Rocha, Petronila Rocha-Pereira, Elisabeth Castro, Vasco Miranda, Maria do Sameiro Faria, Alfredo Loureiro, Alexandre Quintanilha, Luis Belo, Alice Santos-Silva

The Open Clinical Chemistry Journal · 2008

DOI: 10.2174/1874241600801010057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Open Clinical Chemistry Journal, 2008. Verfasst von Elisio Costa und 9 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our aim was to study changes in red blood cell (RBC) membrane band 3 profile, as a cumulative marker of RBC changes, in chronic kidney disease (CKD) patients under haemodialysis and recombinant human erythropoietin (rhEPO) therapy and its linkage with resistance to this therapy.We studied 63 CKD patients, 32 responders and 31 non-responders to rhEPO therapy, and 26 healthy individuals.We evaluated the band 3 profile [% of band 3 monomer, high molecular weight aggregates (HMWAg), and proteolytic fragments (Pfrag)], membrane-bound haemoglobin (MBH), haematological data, total serum bilirubin, glutathione peroxidase (GPx) and superoxide dismutase activities, total antioxidant status (TAS) and plasma lipid peroxidation (TBA).Compared to controls, band 3 profile presented by CKD patients showed statistically significant lower HMWAg and Pfrag values and a significant higher value in band 3 monomer.GPx, TBA and TAS activities, and TBA/TAS ratio were also significantly higher in CKD patients.Comparing responders to non-responders CKD patients, significantly lower value in Pfrag and a trend for a higher value in MBH were found in non-responders.Our data suggest that CKD patients present younger RBC population, which could be related to the rhEPO therapy.The adverse plasma environment associated to CKD patients under hemodialysis imposes changes in band 3 profile, particularly in non-responders, suggesting that resistance to rhEPO therapy in CKD patients seems to be associated to an increase in RBC damage.

Zitieren

APA

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., Miranda, V., Faria, M. D. S., Loureiro, A., Quintanilha, A., Belo, L., & Santos-Silva, A. (2008). Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients. The Open Clinical Chemistry Journal. https://doi.org/10.2174/1874241600801010057

Vancouver

Costa E, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Faria MDS, et al. Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients. The Open Clinical Chemistry Journal. 2008. doi:10.2174/1874241600801010057

BibTeX
@article{Costa2008,
  author = {Costa, Elisio and Rocha, Susana and Rocha-Pereira, Petronila and Castro, Elisabeth and Miranda, Vasco and Faria, Maria do Sameiro and Loureiro, Alfredo and Quintanilha, Alexandre and Belo, Luis and Santos-Silva, Alice},
  title = {Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients},
  journal = {The Open Clinical Chemistry Journal},
  year = {2008},
  doi = {10.2174/1874241600801010057}
}
Kostenlos starten →